$8.59
+0.73
(+9.29%)▲
5.7%
Downside
Day's Volatility :5.7%
Upside
0.0%
43.07%
Downside
52 Weeks Volatility :65.76%
Upside
39.85%
Period | Nano-x Imaging Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -12.28% | 6.5% | 0.0% |
6 Months | 37.65% | 7.1% | 0.0% |
1 Year | -41.99% | 9.8% | 0.0% |
3 Years | -71.57% | 14.2% | -20.2% |
Market Capitalization | 462.3M |
Book Value | $3.2 |
Earnings Per Share (EPS) | -1.08 |
Wall Street Target Price | 14.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -514.1% |
Return On Assets TTM | -15.71% |
Return On Equity TTM | -31.28% |
Revenue TTM | 10.0M |
Revenue Per Share TTM | 0.18 |
Quarterly Revenue Growth YOY | 4.3% |
Gross Profit TTM | -6.9M |
EBITDA | -44.0M |
Diluted Eps TTM | -1.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.87 |
EPS Estimate Next Year | -0.54 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 66.82%
Sell
Neutral
Buy
Nano-x Imaging Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Nano-x Imaging Ltd | 19.09% | 37.65% | -41.99% | -71.57% | -63.78% |
Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Nano-x Imaging Ltd | NA | NA | NA | -0.87 | -0.31 | -0.16 | NA | 3.2 |
Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Nano-x Imaging Ltd | Buy | $462.3M | -63.78% | NA | 0.0% |
Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Nano-x Imaging Ltd
Revenue is down for the last 4 quarters, 2.58M → 2.39M (in $), with an average decrease of 2.4% per quarter
Netprofit is up for the last 3 quarters, -21.40M → -10.24M (in $), with an average increase of 54.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 83.7%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 140.5%
BlackRock Inc
State Street Corporation
Morgan Stanley - Brokerage Accounts
Credit Suisse First Boston (CSFB)
Geode Capital Management, LLC
Point72 Asset Management, L.P.
nanox is developing the next generation of x-ray emitters based on groundbreaking nanotechnology. nanox emitters will finally bring x-ray imaging into the digital era, enabling novel 3d imaging systems with unmatched performance
Organization | Nano-x Imaging Ltd |
Employees | 164 |
CEO | Mr. Erez I. Meltzer |
Industry | Health Technology |
A Spac I Acquisition Corp
$8.59
+9.29%
Keyarch Acquisition Corp
$8.59
+9.29%
Connexa Sports Technologies Inc
$8.59
+9.29%
Us Value Etf
$8.59
+9.29%
First Wave Biopharma Inc
$8.59
+9.29%
Global X Msci Next Emerging
$8.59
+9.29%
Fat Projects Acquisition Corp
$8.59
+9.29%
Capital Link Global Fintech
$8.59
+9.29%
Applied Uv Inc
$8.59
+9.29%